Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | AGPAT2 | O15120 | 9/20 | 0.33 |
| ▸ | GLRA3 | O75311 | 1/20 | 0.33 |
| ▸ | GLRB | P48167 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4282572 | 0.82 | AGPAT2 (0.41) | ALDH1A1KDM4EAGPAT2RECQLMEN1 | |
| SCHEMBL4278355 | 0.80 | AGPAT2 (0.46) | ALDH1A1KDM4EAGPAT2RECQLAMY1A | |
| SCHEMBL4287808 | 0.79 | KDM4E (0.39) | ALDH1A1KDM4ESLC6A4AGPAT2GLRA3 | |
| SCHEMBL4289214 | 0.77 | MAPT (0.42) | ALDH1A1KDM4EAGPAT2GLRA3GLRB | |
| SCHEMBL4284234 | 0.71 | AGPAT2 (0.34) | ALDH1A1KDM4ESLC6A4AGPAT2RECQL | |
| SCHEMBL4280064 | 0.69 | HTR2B (0.38) | ALDH1A1KDM4EAGPAT2RAB9A | |
| SCHEMBL4282527 | 0.67 | HSP90AA1 (0.34) | KDM4ESLC6A4MEN1KMT2ANPC1 | |
| SCHEMBL13880177 | 0.67 | AGPAT2 (0.70) | AGPAT2 | |
| SCHEMBL4291037 | 0.66 | AGPAT2 (0.44) | AGPAT2 | |
| SCHEMBL4285201 | 0.66 | HTR2B (0.35) | ALDH1A1AGPAT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7419984-B2 | Pyrimidines and uses thereof | CELL THERAPEUTICS, INC. (US) | 2008-09-02 | — | — | US | claimed |
| US-20090099183-A1 | PYRIMIDINES AND USES THEREOF | CELL THERAPEUTICS, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| US-7419984-B2 | Pyrimidines and uses thereof | CELL THERAPEUTICS, INC. (US) | 2008-09-02 | — | — | US | disclosed |
| US-20040204386-A1 | Pyrimidines and uses thereof | CELL THERAPEUTICS, INC. | 2004-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204386-A1 | Pyrimidines and uses thereof | LPCAT3, LPCAT1, APRT | ALDH1A1 1326/4885KDM4E 1842/4885SLC6A4 2808/4885 |
| US-20090099183-A1 | PYRIMIDINES AND USES THEREOF | LPCAT3, LPCAT1, APRT | ALDH1A1 1116/4885KDM4E 2160/4885SLC6A4 2939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.